Willow Biosciences Inc. (CSE: WLLW) is “One to Watch”
Exclusive joint development agreement with Noramco, the world’s largest producer of chemically synthesized cannabinoids and pharmaceutical APIs, to commercialize biosynthesized CBD Willow is fully funded with $37 million and expects to have more than $15 million on the balance sheet once the biosynthesized CBD isolate is ready to sell as a product Experienced research team with historical expertise in developing a biosynthesized API derived from the opium poppy, from the bench level to commercial scale-up Established laboratories in Calgary and Vancouver, Canada, and in San Francisco, all undergoing expansion U.S. CBD market potential in excess of $66 billion by 2025…